Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 80 of 1215 for:    "Hodgkin lymphoma"

Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma. (BREACH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02292979
Recruitment Status : Active, not recruiting
First Posted : November 18, 2014
Last Update Posted : March 13, 2019
Sponsor:
Collaborator:
Millennium Pharmaceuticals, Inc.
Information provided by (Responsible Party):
The Lymphoma Academic Research Organisation

Brief Summary:
This study aims to evaluate the efficacy of brentuximab vedotin + AVD combination (doxorubicine, vinblastine, dacarbazine) in patients with Hodgkin lymphoma stage I / II with an unfavorable diagnosis, assessed by the negativity of PET (positron emission tomography ) after two cycles of chemotherapy.

Condition or disease Intervention/treatment Phase
Hodgkin Lymphoma Drug: Doxorubicin Drug: Bleomycin Drug: Vinblastine Drug: Dacarbazine Drug: Brentuximab Vedotin Phase 2

Detailed Description:

Patients will receive either ABVD chemotherapy (standard treatment = doxorubicin, bleomycin, vinblastine, dacarbazine) or the Brentuximab vedotin in combination with chemotherapy AVD (study treatment), depending on randomization. Radiotherapy is planned after chemotherapy or immunochemotherapy.

PET scans will be performed before inclusion, after 2 cycles of chemotherapy and after 4 cycles of chemotherapy (if PET after two cycles was positive), at the end of treatment and during follow-up period.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 170 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Stage I/II Unfavourable Hodgkin Lymphoma. A Randomized Phase II LYSA-FIL-EORTC Intergroup Study
Actual Study Start Date : March 2015
Actual Primary Completion Date : December 2016
Estimated Study Completion Date : August 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: ABVD
Patients in standard arm receive Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine on Day 1 and D14 of each 4-week-cycle during 4 cycles
Drug: Doxorubicin
25mg/m2

Drug: Bleomycin
10mg/m2

Drug: Vinblastine
6mg/m2

Drug: Dacarbazine
375mg/m2

Experimental: AVD+BV
Patients in experimental arm receive Doxorubicin, Vinblastine, Dacarbazine and Brentuximab vedotin on Day 1 and D14 of each 4-week-cycle during 4 cycles
Drug: Doxorubicin
25mg/m2

Drug: Vinblastine
6mg/m2

Drug: Dacarbazine
375mg/m2

Drug: Brentuximab Vedotin
1.2 mg/kg




Primary Outcome Measures :
  1. PET2 assessment [ Time Frame: 8 weeks ]
    Assessment of PET after two cycles according to the five-point scale Deauville criteria (Negative = 1, 2, 3 and Positive = 4, 5), based on central review.


Secondary Outcome Measures :
  1. Complete response (CR) rate [ Time Frame: 16 weeks ]
    according to Cheson 2007 criteria

  2. Progression free survival (PFS) [ Time Frame: 5 years ]
    Survival without disease progression

  3. Overall survival (OS) [ Time Frame: 5 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed CD30+ classical Hodgkin lymphoma
  • Supradiaphragmatic Ann Arbor clinical stage I or II
  • Previously untreated
  • PET scan without IV contrast at diagnosis available for central review with at least one hypermetabolic lesion
  • Unfavourable (U) characteristics according to the classic EORTC/LYSA clinical prognostic factors, including patients with at least one of the following factors:

    • CSII ≥ 4 nodal areas
    • age ≥ 50 yrs
    • M/T ratio ≥ 0.35
    • ESR ≥ 50 (without B-symptoms) or ESR ≥ 30 with B-symptoms
  • ECOG performance status 0-2
  • Life expectancy > 6 months
  • Age 18 to 60 years
  • Availability for periodic blood sampling, study-related assessments, and management of toxicity at the treating institution.
  • Female patients who:

    • Are postmenopausal for at least 1 year before the screening visit, OR are surgically sterile, OR
    • If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, through 6 months after the last dose of study drug, OR agree to completely abstain from heterosexual intercourse
  • Male patients, even if surgically sterilized (ie, status postvasectomy), who:

    o Agree to practice effective barrier contraception during the entire study treatment period and through 6 months after the last dose of study drug, or agree to completely abstain from heterosexual intercourse.

  • Written informed consent.
  • Required baseline laboratory data:

    • Absolute neutrophil count ≥ 1,500/µL
    • Platelet count ≥ 75,000/ µL
    • Hemoglobin ≥ 8g/dL
    • Serum total bilirubin ≤ 1.5 X ULN unless the elevation is known to be due to Gilbert syndrome.
    • Serum creatinine ≤ 2.0 mg/dL and/or calculated creatinine clearance > 40 mL/minute (Cockcroft-Gault formula or MDRD)
    • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 X ULN

Exclusion Criteria:

  • Histological diagnosis different from classical Hodgkin Lymphoma. Nodular lymphocyte predominant subtypes (nodular paragranuloma or Poppema paragranuloma) are excluded.
  • Known cerebral or meningeal disease of any etiology, including signs or symptoms of PML
  • Any sensory or motor peripheral neuropathy ≥ Grade 2
  • Known history of any of the following cardiovascular conditions

    • Myocardial infarction within 2 years of randomization
    • New York Heart Association (NYHA) Class III or IV heart failure (see Appendix 14)
    • Evidence of current uncontrolled cardiovascular conditions, including cardiac arrhythmias, congestive heart failure (CHF), angina, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
    • Recent evidence (within 30 days before first dose of study drug) of a left-ventricular ejection fraction <50%
  • Unstable diabetes mellitus (to avoid uninterpretable FDG-PET scan).
  • Known HIV positive
  • HCV positive
  • HBV positive. This means:

    • HBsAg positive
    • HBsAg negative, anti-HBs positive and/or anti-HBc positive and detectable viral DNA (HBsAg negative patients and viral DNA negative and patients seropositive due to a history of hepatitis B vaccine are eligible).
  • Any history of cancer during the last 5 years, with the exception of non-melanoma skin tumors. Carcinoma in situ of any type not excluded if complete resection.
  • Dementia or altered mental status
  • Pregnancy or breastfeeding.
  • Previous treatment with any anti-CD30 antibody.
  • Known hypersensitivity to any excipients contained in the BV formulation or known contra-indication to any drug contained in the chemotherapy regimens
  • Treatment with corticosteroids before baseline PET scan
  • Known active viral, bacterial, or fungal infection requiring treatment with antimicrobial therapy or with untreated known active Grade 3 viral, bacterial, or fungal infection, within 2 weeks prior to the first dose of BV
  • Treatment with any investigational drug within 30 days before first cycle of treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02292979


  Show 65 Study Locations
Sponsors and Collaborators
The Lymphoma Academic Research Organisation
Millennium Pharmaceuticals, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Marc André, Pr Lymphoma Study Association
Principal Investigator: Luc Fornecker, Dr Lymphoma Study Association

Layout table for additonal information
Responsible Party: The Lymphoma Academic Research Organisation
ClinicalTrials.gov Identifier: NCT02292979     History of Changes
Other Study ID Numbers: BREACH
First Posted: November 18, 2014    Key Record Dates
Last Update Posted: March 13, 2019
Last Verified: March 2019

Keywords provided by The Lymphoma Academic Research Organisation:
HL

Additional relevant MeSH terms:
Layout table for MeSH terms
Hodgkin Disease
Lymphoma
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Doxorubicin
Liposomal doxorubicin
Bleomycin
Vinblastine
Antibodies, Monoclonal
Antibiotics, Antineoplastic
Antineoplastic Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents, Phytogenic
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators